Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2013 | Original Article

Regional distribution and kinetics of [¹⁸F]fluciclovine (anti-[¹⁸F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer

Authors: Jens Sörensen, Rikard Owenius, Michelle Lax, Silvia Johansson

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2013

Abstract

Purpose

[¹⁸F]Fluciclovine (anti-[¹⁸F]FACBC) is a synthetic amino acid developed for PET assessment of the anabolic component of tumour metabolism in clinical routine. This phase 1 trial evaluated the safety, tracer stability and uptake kinetics of [¹⁸F]fluciclovine in patients.

Methods

Six patients with biopsy-proven prostate cancer were investigated with 3-T MRI and PET/CT. All underwent dynamic [¹⁸F]fluciclovine PET/CT of the pelvic area for up to 120 min after injection of 418 ± 10 MBq of tracer with simultaneous blood sampling of radioactivity. The kinetics of uptake in tumours and normal tissues were evaluated using standardized uptake values (SUVs) and compartmental modelling.

Results

Tumour deposits as defined by MRI were clearly visualized by PET. Urine excretion was minimal and normal tissue background was low. Uptake of [¹⁸F]fluciclovine in tumour from the blood was rapid and the tumour-to-normal tissue contrast was highest between 1 and 15 min after injection with a 65 % reduction in mean tumour uptake at 90 min after injection. A one-compartment model fitted the tracer kinetics well. Early SUVs correlated well with both the influx rate constant (K ₁) and the volume of distribution of the tracer (V _T). There were no signs of tracer metabolite formation. The product was well tolerated in all patients without significant adverse events.

Conclusion

[¹⁸F]Fluciclovine shows high uptake in prostate cancer deposits and appears safe for use in humans. The production is robust and the formulation stable in vivo. An early imaging window seems to provide the best visual results. SUV measurements capture most of the kinetic information that can be obtained from more advanced models, potentially simplifying quantification in future studies.

National Cancer Institute. Surveillance Epidemiology and End Results Program. Cancer of the Prostate Statistics. 2010.

Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 1997;33:1075–107.PubMedCrossRef

Engelbrecht MR, Barentsz JO, Jager GJ, van der Graaf M, Heerschap A, Sedelaar JP, et al. Prostate cancer staging using imaging. BJU Int. 2000;86 Suppl 1:123–34.PubMed

Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 2008;49:2031–41.PubMedCrossRef

Jadvar H. Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. Nat Rev Urol. 2009;6:317–23. doi:10.1038/nrurol.2009.81.PubMedCrossRef

Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925–33. doi:10.1148/radiol.09090413.PubMedCrossRef

Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51–60. doi:10.1016/j.eururo.2010.09.004.PubMedCrossRef

Sandblom G, Sörensen J, Lundin N, Häggman M, Malmström P-U. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology. 2006;67:996–1000.PubMedCrossRef

Wachter S, Tomek S, Kurtaran A, Wachter-Gerstner N, Djavan B, Becherer A, et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol. 2006;24:2513–9. doi:10.1200/JCO.2005.03.5279.PubMedCrossRef

10.

Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed

11.

Seppälä J, Seppänen M, Arponen E, Lindholm P, Minn H. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol. 2009;93:234–40.PubMedCrossRef

12.

Jani AB, Fox TH, Whitaker D, Schuster DM. Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design. Clin Nucl Med. 2009;34:279–84.PubMedCrossRef

13.

Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, et al. C11-acetate and F-18FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med. 2011;36:192–8. doi:10.1097/RLU.0b013e318208f140.PubMedCrossRef

14.

Pinkawa M, Holy R, Piroth MD, Klotz J, Nussen S, Krohn T, et al. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol. 2010;186:600–6. doi:10.1007/s00066-010-2122-5.PubMedCrossRef

15.

Meirelles GS, Schoder H, Ravizzini GC, Gonen M, Fox JJ, Humm J, et al. Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res. 2010;16:6093–9. doi:10.1158/1078-0432.CCR-10-1357.PubMedCrossRef

16.

Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56–63.PubMed

17.

Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med. 2007;48:1017–20.PubMedCrossRef

18.

Asano Y, Inoue Y, Ikeda Y, Kikuchi K, Hara T, Taguchi C, et al. Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[18F]FACBC. Ann Nucl Med. 2011;25:414–8. doi:10.1007/s12149-011-0477-z.PubMedCrossRef

19.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci. 2008;99:2380–6. doi:10.1111/j.1349-7006.2008.00969.x.PubMedCrossRef

20.

McParland BJ, Lax M, Axelsson J, Wall A, Johansson S, Sorensen J. The biodistribution and internal radiation dosimetry of [18F]GE-148 in healthy adult volunteers. Eur J Nucl Med Mol Imaging. 2010;37 (Suppl 2):S287

21.

McConathy J, Voll RJ, Yu W, Crowe RJ, Goodman MM. Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. Appl Radiat Isot. 2003;58:657–66.PubMedCrossRef

22.

Kessler RM, Ellis Jr JR, Eden M. Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr. 1984;8:514–22.PubMedCrossRef

23.

Carson R. Mathematical modeling and compartmental analysis. In: Harbert J, Eckelman WC, Neumann R, editors. Nuclear medicine: diagnosis and therapy. New York: Thieme Medical Publishers; 1996. p. 167–94.

24.

Meyer E. Simultaneous correction for tracer arrival delay and dispersion in CBF measurements by the H215O autoradiographic method and dynamic PET. J Nucl Med. 1989;30:1069–78.PubMed

25.

Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716–23. doi:10.1109/TAC.1974.1100705.CrossRef

26.

Schiepers C, Hoh CK, Nuyts J, Seltzer M, Wu C, Huang SC, et al. 1-11C-acetate kinetics of prostate cancer. J Nucl Med. 2008;49:206–15. doi:10.2967/jnumed.107.044453.PubMedCrossRef

27.

Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3:6–12.PubMedCrossRef

28.

Higgins KA, Hoang JK, Roach MC, Chino J, Yoo DS, Turkington TG, et al. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUV(mean) has superior prognostic value. Int J Radiat Oncol Biol Phys. 2012;82:548–53. doi:10.1016/j.ijrobp.2010.11.050.PubMedCrossRef

29.

Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, Patz EF. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol. 2008;26:1459–64. doi:10.1200/jco.2007.14.3628.PubMedCrossRef

Title: Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer
Authors: Jens Sörensen
Rikard Owenius
Michelle Lax
Silvia Johansson
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-012-2291-9

2024 ASCO Annual Meeting

Springer Medicine

Regional distribution and kinetics of [¹⁸F]fluciclovine (anti-[¹⁸F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer

Abstract

Purpose

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2013

FDG PET imaging for diagnosing prosthetic joint infection: discussing the facts, rectifying the unsupported claims and call for evidence-based and scientific approach

Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response

[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours

Performance of orthopantomography, planar scintigraphy, CT alone and SPECT/CT in patients with suspected osteomyelitis of the jaw

Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer: a systemic review and meta-analysis

Simultaneous PET/MRI in frontotemporal dementia